Direct Acting Antivirals For Hepatitis C

  • by Medembassy

Hepatitis C virus nucleic acid (RNA - HCV) positive, the virus in the continuous replication, the liver function is difficult to stabilize, the majority of patients, serum aminotransferase (ALT) showed mild or moderate increase. These patients should antiviral therapy and treatment of liver.

After many years of clinical validation, the use of ordinary interferon, 50% of patients can get a better effect, that is, the serum RNA - HCV negative conversion, liver function to return to normal. But after discontinuation of interferon, 10% to 15% of patients with viral replication rebound, that is, RNA - HCV positive, liver function again abnormal. In recent years, with the clinical application of interferon combined with ribavirin in hepatitis C patients, curative effect is improved by 20% ~ 30% than before, the current can reach 80% ~ 90%. Particularly gratifying is that the rebound rate is significantly reduced.

The application dose of long acting interferon as before, the virus is 800 ~ 1200 mg / day, divided into 3 oral. The course of treatment should be in 12 ~ 6 months. If you can persist for 12 months of treatment, liver function and hepatitis C virus rebound rate is generally below 5%. Therefore, some scholars believe that the treatment of long-term interferon combined with viral therapy for the treatment of hepatitis C has brought a bright future.

Hepatitis c is a global epidemic, can lead to chronic inflammation of the liver necrosis and fibrosis, some patients may develop liver cirrhosis and hepatocellular carcinoma (HCC).

Viral hepatitis c, for short, is a kind of caused by hepatitis c virus (HCV) infection in viral hepatitis, main transmission through blood transfusion, acupuncture, drugs, etc, according to the world health organization, the world of HCV infection rate is about 3%, an estimated 180 million people are infected with HCV, every year around 35000 new cases of hepatitis c patients.

Over the next 20 years mortality associated with HCV infection (liver failure and hepatocellular carcinoma (HCC) deaths) will continue to increase, great harm to patients health and life, has become a serious social and public health problems.

Harvoni:For 1, 4, 6, type c without interferon, it was the first to cure hepatitis c without the need for joint interferon hepatitis c drugs. For hepatitis c type 1 patients has a high cure rate of 95%, and side effects are very small, and also had a shorter treatment time.

Sofosbuvir:The drug is first without joint interferon can be safe and effective drug for the treatment of certain types of hepatitis c. Clinical trials confirm for type 1 and 4 c, the drug combination of polyethylene glycol (peg) interferon and ribavirin overall sustained virological response (SVR) is as high as 90%; In view of the type 2 c, the drug plus ribavirin SVR is 89% - 95%; In view of the 3 c, the drug plus ribavirin SVR is 61% - 63%.

Who is your best choice?
Medembassy

Registration hotline: (001)4152318413